Tags : its Select Non-Core Assets

Takeda Divests its Select Non-Core Assets in the EU and

Shots: Takeda will receive $562M up front for divesting its non-core prescription pharmaceutical products targeting a variety of therapeutic categories sold predominantly in the EU and Canada The divested portfolio includes Takeda’s CV/ metabolic and anti-inflammatory therapeutic areas along with Calcium. The portfolio generated FY 2019 net sales of ~$260M The divestiture further enables Takeda’s […]Read More